2020
DOI: 10.4070/kcj.2020.0308
|View full text |Cite
|
Sign up to set email alerts
|

Percutaneous Edge-to-Edge Mitral Valve Repair

Abstract: Percutaneous edge-to-edge mitral valve repair, using the MitraClip device for severe mitral regurgitation (MR) was first introduced in 2003. Since then, more than 100,000 cases have been performed worldwide and it remains the most established percutaneous therapy available for the treatment of severe MR. Currently, it is indicated for severe, symptomatic functional MR in patients who continue to have significant symptoms despite optimal guideline directed medical therapy, as well as in symptomatic patients wit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
5
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 45 publications
0
5
0
Order By: Relevance
“…“G4” features a novel side-dependent grasping and real-time left atrial pressure monitoring. Furthermore, preparation is simplified and steering more precise [ 16 ••, 17 , 18 ].…”
Section: Evolution Of MCmentioning
confidence: 99%
“…“G4” features a novel side-dependent grasping and real-time left atrial pressure monitoring. Furthermore, preparation is simplified and steering more precise [ 16 ••, 17 , 18 ].…”
Section: Evolution Of MCmentioning
confidence: 99%
“…The following reasons have been proposed for these discordant results [ 11 - 13 ]. First, the definitions of severe MR were different between European and American guidelines.…”
Section: Recent Clinical Trials and Evidence For Teermentioning
confidence: 99%
“…In contrast, patients with an effective regurgitant orifice area of 0.3 to 0.4 cm 2 , but with an LV end-diastolic volume of only 160 to 200 mL, exhibit degrees of MR that are disproportionately higher than would be predicted by LV end-diastolic volume. Thus, these patients were proposed to preferentially benefit from interventions directed at the mitral valve [ 11 - 13 ].…”
Section: Recent Clinical Trials and Evidence For Teermentioning
confidence: 99%
“…Transcatheter edge-to-edge mitral valve repair (TEER), using the MitraClip device for severe mitral regurgitation (MR) was first introduced in 2003. Since then, it has remained the most established percutaneous therapy available for the treatment of severe MR. 1) Current guidelines recommend it is indicated for severe, symptomatic functional MR in patients who continue to have significant symptoms despite optimal guideline-directed medical therapy, as well as in symptomatic patients with severe degenerative MR who are deemed too high risk for conventional surgical therapy in the opinion of the heart team. 2) …”
mentioning
confidence: 99%